Quadrant Drug Delivery Limited

Quadrant Holdings Cambridge Limited

Cambridge Biostability Ltd.

Elan Drug Delivery Limited

Quadrant Bioresources Limited

Quandrant Drug Delivery Limited

Quadrant Healthcare (uk) Limited

Stablepharma Ltd

Nova Bio-pharma Technologies Limited

Peter M. Ronai

Quardrant Holdings Cambridge, Ltd.

Quandrant Holdings Cambridge Limited

Bruce J Roser

Camilo Colaco

Jaap Kampinga

Julian Blair

David Moss

Shevanti Sen

Enda Martin Gribbon

Valentine Menys

Arcadio Garcia De Castro

Diana Phipps

James Maki

Ross Henry Hatley

Mohammed A Z Jerrow

Alan G Tunnacliffe

Christopher Smith

Lynda Grandage

James Lewis Wardell

John Alistair Duffy

Ian Sanderson

Samodh De Costa

Kamaljit S Dhaliwal

David T Welsh

A syringe containing a compressible porous matrix, which compressible porous matrix has in it a pharmaceutical in a soluble glass, Methods of producing and using the syringe, and compressible porous matrix inserts for insertion into a syringe barrel are also provided.

Injections

Biological materials such as vaccines can be stabilized in certain glassy materials soluble in water. It has been proposed to form these glassy materials as a powder suspended in a non-aqueous liquid for injection into a patient. This method is complicated by the need to find suitable compatible liquids and to stop the glassy particles from congregating in liquid. These problems have been obviated by supporting the glassy material on a porous membrane remote from the eluant. When the biological material requires administration, the eluant can be passed across the membrane dissolving the glass and causing the substance to be carried by the liquid into the patient.

Pharmaceutical device for the administration of substances to patients

A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.

Dried blood factor composition comprising trehalose

The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.

Solid dose delivery vehicle and methods of making same

The present invention encompasses a therapeutic composition in solid dose form that is suitable for pulmonary administration. The therapeutic composition may comprise therapeutic particles in a glassy state. The therapeutic composition preferably comprises a bioactive material such as insulin, and a sugar alcohol. The components are optionally in solid solution. The therapeutic composition can preferably remain in a glassy state when stored at elevated temperatures, and/or extended periods.

A stable blood factor composition contains a stabilizing amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60&#xb0; C.

A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60&#xb0; C.

Dried blood factor composition trehalose

The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical.

Method for stably incorporating substances within dry, foamed glass matrices

Growing community of inventors

Cambridge, United Kingdom

Bruce J Roser